Last reviewed · How we verify
Microscopic polyarteritis nodosa — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Mabthera | rituxan | Roche | CD20-directed Cytolytic Antibody | B-lymphocyte antigen CD20 | 1997-01-01 | |
| Mabthera | Rituximab-Pvvr | Roche | Monoclonal antibody | CD20 antigen on pre-B and mature B-lymphocytes | 1997-01-01 | |
| Mabthera | rituximab | Roche | CD20-directed Cytolytic Antibody [EPC] | B-lymphocyte antigen CD20 | 1997-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Roche · 3 drugs in Microscopic polyarteritis nodosa
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Microscopic polyarteritis nodosa:
- Microscopic polyarteritis nodosa treatment updates — RSS
- Microscopic polyarteritis nodosa treatment updates — Atom
- Microscopic polyarteritis nodosa treatment updates — JSON
Cite this brief
Drug Landscape (2026). Microscopic polyarteritis nodosa — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/microscopic-polyarteritis-nodosa. Accessed 2026-06-10.
Related
- Microscopic polyarteritis nodosa full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing